Treatment of asthma with anti–immunoglobulin E monoclonal antibody
Abstract:Clinical experience with anti–immunoglobulin E monoclonal antibody therapy (i.e., omalizumab) for asthma is maturing. Now several years after U.S. Food and Drug Administration approval and release, more studies of the clinical efficacy and safety of omalizumab have been published. We are gaining a better understanding of those patients with asthma who are likely to benefit from the therapy. The large majority of patients with asthma who meet the U.S. Food and Drug Administration–approved criteria for omalizumab therapy have severe persistent asthma. Additionally, in patients with severe disease, several predictive markers of clinical improvement with omalizumab therapy have been identified recently. There is good reason to have increasing comfort with omalizumab therapeutic trials, especially in those with severe asthma.
Document Type: Research Article
Publication date: March 1, 2006
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites